{
  "id": 18415892,
  "title": "Martine Rothblatt, United Therapeutics CEO, sells $4.66M in shares",
  "url": "https://urgent.news/2026/11/06/martine-rothblatt-united-therapeutics-ceo-sells-4-66m-in-shares",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-06T01:31:30.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/martine-rothblatt-united-therapeutics-ceo-sells-466m-in-shares-93CH-5006270"
  },
  "original_language": "en",
  "account": "Martine A. Rothblatt, the Chairperson and CEO of United Therapeutics Corp (NASDAQ:UTHR), sold $4.66 million worth of shares on November 4, 2026. She disposed of 7,748 shares, priced between $580.70 and $609.09 per share. The transactions were executed under a pre-approved 10b5-1 plan, and Rothblatt now owns 326,166 shares indirectly through a trust, along with 90,910 options held indirectly. United Therapeutics' strong cash position, 86% gross profit margin, and robust product demand led to record third-quarter revenue of $832.5 million, even though earnings per share fell short of estimates.",
  "summary": null,
  "key_points": [
    "Martine Rothblatt sold $4.66M in United Therapeutics shares on Nov 4, 2026",
    "CEO disposed of 7,748 shares at $580.70-$609.09 per share",
    "Rothblatt retains 326,166 shares and 90,910 options indirectly"
  ],
  "editors_take": "Executing these sales through a pre-approved plan allows the chief executive to liquidate significant holdings without disrupting investor confidence in the company's strong profit margins and revenue growth.",
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}